DDInter1526 DDInter1676
An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Procarbazine {u} (Compound) resembles {v} (Compound) Atenolol
Procarbazine {u} (Compound) treats {v} (Disease) hematologic cancer
Procarbazine {u} (Compound) binds {v} (Gene) CYP1B1
Procarbazine {u} (Compound) upregulates {v} (Gene) MOK
Procarbazine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Procarbazine {u} (Compound) downregulates {v} (Gene) DLD
Procarbazine {u} (Compound) causes {v} (Side Effect) Headache
Procarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Procarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Procarbazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Guanadrel
Procarbazine (Compound) resembles Atenolol (Compound)
Procarbazine (Compound) treats hematologic cancer (Disease)
Procarbazine (Compound) binds CYP1B1 (Gene)
Procarbazine (Compound) upregulates MOK (Gene)
Procarbazine (Compound) is included by Alkylating Activity (Pharmacologic Class)
Procarbazine (Compound) downregulates DLD (Gene)
Procarbazine (Compound) causes Headache (Side Effect)
Procarbazine may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Procarbazine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel